Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (6031)	11/25/1998 7:50:00 PM
From: Heat Shock	Read Replies (2) \| Respond to of 9719

To all: someone here called for 10/100-bagger candidates. Allow me to emerge from long-time lurking to present StressGen Biotechnologies- SSB on Toronto Stock Exchange, Yahoo quote SSB.TO. StressGen's platform is based on the ability of Stress Proteins to potently activate the immune system to destroy cancer cells and virally-infected cells. Stress Proteins occur in all life and function to ensure that proteins are folded correctly. StressGen has 2 INDs which were to be filed in 4Q/98. 1. lead product HspE7 therapeutic vaccine for cervical dysplasia (precancerous cells leading to cervical cancer). This fusion vaccine joins a stress protein from a bacterium with the E7 antigen from HPV, the Human Papilloma Virus. Mouse studies with HspE7 show that cervical cancers go away, and are rejected on a second challenge with cancer cells. If memory serves, there was some merry hijinx on this thread centred around genital warts. The target of this therapeutic vaccine, HPV, is not only the most common sexually transmitted bug, but it causes genital warts! Hey. Consider genital warts, get a 100-bagger. 2. joint venture with Genzyme (GZMO) with profits 50/50. GZMO's liposomal gene delivery delivers a gene for a bacterial stress protein into cancer cells, which express the foreign stress proteins, which make cancer cells visible to T-cells, which kill the cancer cells. The joint venture's exact type of therapy and the indication are being worked on. StressGen share price (Canadian dollars) rose to over $5.00 on anticipation of a deal with a larger company. I think investors were thinking of Merck or someone like that. When it turned out to be Genzyme, the share price plummeted. It trades now at $1.50 or so, not far from cash value. Neat site with pretty colour pictures of stress proteins explaining some of the science: tulane.edu StressGen thread on SI: exchange2000.com:80/~wsapi/investor/Subject-4811 StressGen web site: stressgen.com Happy American Thanksgiving. Heat.